Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Pesquisa Study Connect
  • NCT03989414

Recruiting

A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - CC-92480-MM-002

Atualizado: 8 janeiro, 2024   |   ClinicalTrials.gov

Celgene é uma subsidiária integral da Bristol-Myers Squibb 

Imprima o Resumo

CONSIDERANDO ESTE ESTUDO?
Imprima esta página e o guia de estudo para ajudá-lo a conversar com seu médico.
Use o guia de estudo para navegar no processo de participação em um estudo clínico. Entenda os principais fatores a serem considerados antes de decidir e faça perguntas para sua equipe de saúde.
Imprimir esta página CC-92480-MM-002
Baixar o guia

SELECIONAR IDIOMA

Detalhes do estudo

  • Phase 1/Phase 2

    Fase

  • Gênero(s)

  • 18+

    Faixa etária

  • 26

    Localização(ões)

  • Recruiting

Opções de tratamento

Braços de tratamento do Estudo
INTERVENÇÃO ATRIBUÍDA
Experimental: CC-92480 in combination with bortezomib and dexamethasone
Drug: Bortezomib, Dexamethasone, CC-92480
Experimental: CC-92480 in combination with carfilzomib and dexamethasone
Drug: Elotuzumab, Dexamethasone, CC-92480
Experimental: CC-92480 in combination with daratumumab and dexamethasone
Drug: Carfilzomib, CC-92480, Dexamethasone
Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
Drug: Carfilzomib, Dexamethasone, CC-92480
Experimental: Cohort E: CC-92480 with daratumumab and dexamethasone
Drug: Dexamethasone, Elotuzumab, CC-92480
Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
Drug: Dexamethasone, CC-92480, Isatuximab
Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Cohort H: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Dexamethasone, Isatuximab
Experimental: Cohort I: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort J: CC-92480 with elotuzumab and dexamathasone
Drug: CC-92480, Bortezomib, Dexamethasone
Experimental: Cohort K: CC-92480 with isatuximab and dexamathasone
Drug: CC-92480, Dexamethasone, Daratumumab
Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone
Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
Drug: CC-92480, Daratumumab, Dexamethasone

Principais critérios de elegibilidade

Inclusion Criteria: 1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen. 3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma. 4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan. Exclusion Criteria: 1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas

Tem dúvidas? Envie-nos um email.

Tem dúvidas?
Envie-nos um email.